Payment overview · 2025
General Payments
$847.18
45 reported records · 8 companies
Healthcare provider profile · identity verified
Stephen M Reeder, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1356441851
Verified facts
What the public records show
CMS Open Payments records show Stephen M Reeder, MD received $847.18 in general payments during 2025 across 45 reported records.
Abbott Laboratories accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Wegovy.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $264.57 | 31.2% | 13 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $181.95 | 21.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.89 | 18.9% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.63 | 8.5% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.20 | 6.2% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $49.66 | 5.9% | 3 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $43.06 | 5.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.22 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $847.18 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $264.57 | 13 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $181.95 | 5 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $60.03 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.84 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $52.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.20 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $43.06 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $43.02 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.58 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.06 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 156 |
| Lisinopril | Lisinopril | 588 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 521 | 91 |
| Alprazolam | Alprazolam | 518 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 492 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 456 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 74 |
| Losartan Potassium | Losartan Potassium | 320 | 82 |
| Gabapentin | Gabapentin | 311 | 62 |
| Omeprazole | Omeprazole | 303 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 74 |
| Tramadol Hcl | Tramadol Hcl | 281 | 59 |
| Furosemide | Furosemide | 276 | 65 |
| Simvastatin | Simvastatin | 267 | 65 |
| Metformin Hcl | Metformin Hcl | 265 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 238 | 58 |
| Eliquis | Apixaban | 215 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 56 |
| Trazodone Hcl | Trazodone Hcl | 193 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 35 |
| Carvedilol | Carvedilol | 178 | 39 |
| Potassium Chloride | Potassium Chloride | 173 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 34 |
| Lorazepam | Lorazepam | 162 | 27 |
| Azithromycin | Azithromycin | 157 | 111 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 155 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 151 | 31 |
| Jardiance | Empagliflozin | 142 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 28 |
| Famotidine | Famotidine | 129 | 34 |
| Montelukast Sodium | Montelukast Sodium | 121 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 32 |
| Ozempic | Semaglutide | 112 | 14 |
| Allopurinol | Allopurinol | 111 | 32 |
| Pregabalin | Pregabalin | 101 | 15 |
| Cefdinir | Cefdinir | 93 | 71 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 54 |
| Xarelto | Rivaroxaban | 86 | 15 |
| Spironolactone | Spironolactone | 85 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 83 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 83 | 21 |
| Celecoxib | Celecoxib | 82 | 18 |
| Estradiol | Estradiol | 82 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 17 |
| Valsartan | Valsartan | 78 | 21 |
| Metformin Hcl Er | Metformin Hcl | 77 | 16 |
| Methylprednisolone | Methylprednisolone | 77 | 55 |
| Prednisone | Prednisone | 77 | 37 |
| Sertraline Hcl | Sertraline Hcl | 76 | 20 |
| Meloxicam | Meloxicam | 75 | 20 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 13 |
| Cephalexin | Cephalexin | 70 | 38 |
| Finasteride | Finasteride | 68 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 16 |
| Irbesartan | Irbesartan | 65 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 17 |
| Mounjaro | Tirzepatide | 61 | suppressed |
| Torsemide | Torsemide | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 58 | 11 |
| Glimepiride | Glimepiride | 57 | 11 |
| Mirtazapine | Mirtazapine | 57 | suppressed |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 55 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 11 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 48 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 21 |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 11 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Diazepam | Diazepam | 43 | 15 |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Naproxen | Naproxen | 42 | suppressed |
| Acyclovir | Acyclovir | 41 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 12 |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Glipizide | Glipizide | 33 | suppressed |
| Premarin | Estrogens, Conjugated | 33 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 20 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 15 |
| Linzess | Linaclotide | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | 12 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $847.18 · 45 records | Abbott Laboratories | CRYSVITA, EVENITY, FREESTYLE LIBRE, LEQVIO, Ozempic, PROLIA, REPATHA, Rybelsus, Senza, TEPEZZA, Tymlos, Wegovy, XYOSTED | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error